Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy

Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment. However, only a fraction of the patients respond to ICB therapy. Accurate prediction of patients to likely respond to ICB would maximize the efficacy of ICB therapy. The tumor microenvironment (TME) dictates tumor progression and therapy outcome. Here, we classify the TME by analyzing the transcriptome from 11,069 cancer patients based on angiogenesis and T-cell activity. We find three distinct angio-immune TME subtypes conserved across 30 non-hematological cancers. There is a clear inverse relationship between angiogenesis and anti-tumor immunity in TME. Remarkably, patients displaying TME with low angiogenesis with strong anti-tumor immunity show the most significant responses to ICB therapy in four cancers. Re-evaluation of the renal cell carcinoma clinical trials provides compelling evidence that the baseline angio-immune state is robustly predictive of ICB responses. This study offers a rationale for inco..., Data files are derived from processing as derived from manuscript. Code to generate angio-immune clusters is provided., , # Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy

Data files are derived from processing as derived from manuscript. Code to generate angio-immune clusters is provided.

All data analyzed is from previously published datasets. Enrichment results files contain GSVA enrichment results used to derive angio-immune clusters. Clinical files contain information on response/survival status. R code to generate clusters 

## Description of the data and file structure

**Data hosted on Dryad**:

* angio-immune-clusters.xlsx - provides the cluster information for all TCGA patients analyzed
* cluster = Pan cancer angio-immune cluster label 
* x = TCGA sample names

**Data hosted on Zenodo**:

* Bladder-Cancer-Enrichment-Results.txt - provides enrichment results for anti-PDL1 pre-treatment patients with bladder cancer. Enrichment results range from -1 to 1
* Column names are sample IDs 
* Row names are individual pathways ...